Balyasny Asset Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.5M | Buy |
+2,865,625
| New | +$6.5M | 0.01% | 807 |
|
|
2024
Q2 | – | Sell |
-31,921
| Closed | -$69.6K | – | 2003 |
|
|
2024
Q1 | $69.6K | Buy |
+31,921
| New | +$69.6K | ﹤0.01% | 1890 |
|
|
2023
Q1 | – | Sell |
-34,800
| Closed | -$55.7K | – | 2275 |
|
|
2022
Q4 | $55.7K | Buy |
34,800
+20,006
| +135% | +$32K | ﹤0.01% | 1895 |
|
|
2022
Q3 | $21K | Sell |
14,794
-1,758
| -11% | -$2.5K | ﹤0.01% | 2091 |
|
|
2022
Q2 | $30K | Buy |
+16,552
| New | +$30K | ﹤0.01% | 1974 |
|
|
2021
Q3 | – | Sell |
-10,059
| Closed | -$64K | – | 1725 |
|
|
2021
Q2 | $64K | Buy |
+10,059
| New | +$64K | ﹤0.01% | 1552 |
|
|
2018
Q3 | – | Sell |
-16,632
| Closed | -$380K | – | 1487 |
|
|
2018
Q2 | $380K | Buy |
16,632
+1,157
| +7% | +$26.4K | ﹤0.01% | 1252 |
|
|
2018
Q1 | $440K | Buy |
+15,475
| New | +$440K | ﹤0.01% | 1294 |
|